Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sulfonylurea

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    143 result(s) found for: Sulfonylurea. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2004-001546-32 Sponsor Protocol Number: CLAF237A2305 Start Date*: 2004-09-07
    Sponsor Name:Novartis Finland Oy
    Full Title: A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with ...
    Medical condition: Patients with type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004667-36 Sponsor Protocol Number: SYR-322-SULF-007 Start Date*: 2006-05-26
    Sponsor Name:Takeda Global Research & Development Center, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with a Sulfonylurea in Subjects with Type 2 Di...
    Medical condition: Type II diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002118-39 Sponsor Protocol Number: 0000-027-00 Start Date*: 2005-07-12
    Sponsor Name:Merck & Co., Inc.
    Full Title: RECAP-DM (Real-life Effectiveness and Care Patterns of Diabetes Management)
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-004798-60 Sponsor Protocol Number: CL3-00780-148 Start Date*: Information not available in EudraCT
    Sponsor Name:I.R.I.S. Institut de Recherches Internationales Servier
    Full Title: A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonyl...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012613 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-009157-24 Sponsor Protocol Number: BC21893 Start Date*: 2009-06-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio multicéntrico, randomizado, doble ciego, con doble enmascaramiento,  controlado frente a un comparador activo para evaluar la eficacia, seguridad y tolerancia de taspoglutida (RO5073031) co...
    Medical condition: Pacientes con diabetes mellitus tipo 2 Patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    9 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003118-86 Sponsor Protocol Number: 1218.35 Start Date*: 2009-02-10
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 18 weeks in Type 2 diabetic patients with insufficient ...
    Medical condition: Type 2 diabetes with insufficient glycaemic control (HbA1c 7.0-10%) despite background therapy with a sulfonylurea drug
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-016604-23 Sponsor Protocol Number: CACZ885I2207 Start Date*: 2010-05-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...
    Medical condition: Impaired Glucose Tolerance and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002826-35 Sponsor Protocol Number: EFC14835 Start Date*: 2017-04-24
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea alone or in combination with Metformin...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SK (Completed) HU (Completed) GB (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002911-24 Sponsor Protocol Number: H9X-MC-GBDG Start Date*: 2013-04-19
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-005881-11 Sponsor Protocol Number: EFC6015 Start Date*: 2008-07-18
    Sponsor Name:Sanofi-Aventis Recherche&Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in pat...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    10.1 10067585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019428-30 Sponsor Protocol Number: D1680L00006 Start Date*: 2010-05-14
    Sponsor Name:AstraZeneca Singapore Pte Ltd
    Full Title: A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb tudy to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin and Sulfonylurea in Subjects wi...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016258-41 Sponsor Protocol Number: 1245.23 Start Date*: 2010-08-10
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with type 2...
    Medical condition: The study will be performed in patients (age of 18 or more) with type 2 diabetes and insufficient glycaemic control despite a background therapy of metformin or metformin plus a sulfonylurea.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) SI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-009500-39 Sponsor Protocol Number: H8O-EW-GWDM Start Date*: 2009-06-18
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized Trial Comparing two therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects wit...
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PT (Completed) SE (Completed) FI (Completed) ES (Completed) NL (Completed) BE (Completed) IT (Completed) GR (Completed) EE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006054-82 Sponsor Protocol Number: CL2-05720-005 Start Date*: 2012-06-29
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin (metformin XR) in type 2 diabetic patients previously treated with metformin in combina...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004990-34 Sponsor Protocol Number: MK-0431-845 Start Date*: 2016-05-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin...
    Medical condition: Type 2 Diabetes Mellitus (T2DM)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) LV (Completed) CZ (Completed) ES (Completed) DK (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005326-19 Sponsor Protocol Number: NN9924-4234 Start Date*: 2016-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002231-26 Sponsor Protocol Number: D1693C00005 Start Date*: 2011-09-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study with a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg once da...
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011965-10 Sponsor Protocol Number: AT130-G-08-006 Start Date*: 2009-08-14
    Sponsor Name:Akros Pharma Inc.
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study Evaluating the Efficacy, Safety and Tolerability of JTT-130 Administered Twice Daily for 24 Weeks in Tre...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    11.1 10012601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-006719-20 Sponsor Protocol Number: 0431-082 Start Date*: 2009-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
    Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004672-20 Sponsor Protocol Number: SYR-322-OLE-012 Start Date*: 2006-04-24
    Sponsor Name:Takeda Global Research & Development Center, Inc.,
    Full Title: A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:45:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA